UK Medical Research Council CLL3 - A randomized trial of the addition of epirubicin to standard chlorambucil treatment.

UK Medical Research Council CLL3 - A randomized trial of the addition of epirubicin to standard chlorambucil treatment.

Podrobná bibliografie
Hlavní autoři:	Catovsky, D, Hamblin, T, Richards, S, Party, M
Médium:	Journal article
Vydáno:	2000

Podobné jednotky

Preliminary results of the UK Medical Research Council trial in chronic lymphocytic leukaemia - CLL3
Autor: Catovsky, D, a další
Vydáno: (1998)

Early results from LRF CLL4: A UK multicenter randomized trial
Autor: Catovsky, D, a další
Vydáno: (2005)

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
Autor: Hillmen, P, a další
Vydáno: (2006)

Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
Autor: Else, M, a další
Vydáno: (2006)

Prognostic factors in the UK LRF CLL4 trial
Autor: Oscier, D, a další
Vydáno: (2006)

Prognostic factors in the UK LRF CLL4 trial.
Autor: Oscier, D, a další
Vydáno: (2006)

Prognostic factors in the UK LRF CLL4 trial.
Autor: Oscier, D, a další
Vydáno: (2005)

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
Autor: Dearden, C, a další
Vydáno: (2007)

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial.
Autor: Bosanquet, A, a další
Vydáno: (2006)

The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial.
Autor: Catovsky, D, a další
Vydáno: (2006)

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
Autor: Hillmen, P, a další
Vydáno: (2005)

Quality of life in the LRF CLL4 trial.
Autor: Else, M, a další
Vydáno: (2005)

Incidence of hemolytic anemia after chemotherapy in the CLL4 trial. A possible protective role for fludarabine plus cyclophosphamide.
Autor: Catovsky, D, a další
Vydáno: (2004)

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)
Autor: Hillmen, P, a další
Vydáno: (2014)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
Autor: Catovsky, D, a další
Vydáno: (2004)

Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
Autor: Else, M, a další
Vydáno: (2012)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
Autor: Catovsky, D, a další
Vydáno: (2006)

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
Autor: Matutes, E, a další
Vydáno: (2013)

The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry
Autor: Matutes, E, a další
Vydáno: (2013)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
Autor: Dearden, C, a další
Vydáno: (2011)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Autor: Othman Al-Sawaf, a další
Vydáno: (2023-04-01)

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.
Autor: Sellick, G, a další
Vydáno: (2008)

Azathioprine, cyclophosphamide and chlorambucil.
Autor: Luqmani, R, a další
Vydáno: (1990)

Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults.
Autor: Durrant, I, a další
Vydáno: (1997)

Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.
Autor: Catovsky, D, a další
Vydáno: (1989)

Baseline characteristics associated with quality of life in CLL patients requiring therapy
Autor: Else, M, a další
Vydáno: (2007)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Autor: Othman Al-Sawaf, a další
Vydáno: (2023-10-01)

Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL)
Autor: Binet, J, a další
Vydáno: (1998)

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.
Autor: Allan, N, a další
Vydáno: (1995)

Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial.
Autor: Else, M, a další
Vydáno: (2008)

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.
Autor: Oscier, D, a další
Vydáno: (2010)

Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.
Autor: Mitchell, C, a další
Vydáno: (2005)

Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia.
Autor: Chessells, J, a další
Vydáno: (1995)

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation
Autor: David Oscier, a další
Vydáno: (2010-10-01)

Chlorambucil-Induced Acute Interstitial Pneumonitis
Autor: Hammad Shafqat, a další
Vydáno: (2014-01-01)

Rapid desensitization for chlorambucil drug fever
Autor: E Weber, a další
Vydáno: (2007-07-01)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Autor: Catovsky, D, a další
Vydáno: (2007)

Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial)
Autor: McClanahan, F, a další
Vydáno: (2010)

Comparison of ZAP-70, IgVH gene mutational status and CD38 in CLL patients requiring therapy: Preliminary report from the UKCLL IV trial.
Autor: Orchard, J, a další
Vydáno: (2003)

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.
Autor: Richards, S
Vydáno: (1999)